Keryx Biopharmaceuticals (KERX) : During the past 4 weeks, traders have been relatively bearish on Keryx Biopharmaceuticals (KERX), hence the stock is down -40.11% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.51% relative to the S&P 500. The 4-week change in the price of the stock is -39.49% and the stock has fallen -4.45% in the past 1 week.
The stock has recorded a 20-day Moving Average of 28.6% and the 50-Day Moving Average is 31.36%. Keryx Biopharmaceuticals (NASDAQ:KERX): stock turned positive on Friday. Though the stock opened at $4.27, the bulls momentum made the stock top out at $4.33 level for the day. The stock recorded a low of $4.26 and closed the trading day at $4.29, in the green by 0.47%. The total traded volume for the day was 611,273. The stock had closed at $4.27 in the previous days trading.
The company Insiders own 3.08% of Keryx Biopharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -1.83% . Institutional Investors own 61.14% of Keryx Biopharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -3.44%. Also, Equity analysts at the Brokerage firm Stifel Nicolaus downgrades its rating on Keryx Biopharmaceuticals (NASDAQ:KERX). The rating major has initiated the coverage with hold rating on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on August 2, 2016.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).